Phase 1/2 Data Show Potential of VX-880 for Insulin Independ

New results from the ongoing clinical trial of VX-880 suggested all patients with T1D treated with the novel stem cell-derived islet cell therapy showed restored endogenous insulin secretion and improved glycemic control.

Related Keywords

Switzerland , Netherlands , Toronto , Ontario , Canada , United States , Norway , American , Trevorw Reichman , , Scientific Sessions Of The American Diabetes Association , University Of Toronto , Ajmera Transplant Center , University Of Toronto Trevorw Reichman , Scientific Sessions , American Diabetes Association ,